Keywords: Mylan, South Africa, ARV launches, HIV/AIDS drugs

Mylan debuts HIV/AIDS drug portfolio in South Africa

Article | 24 February 2013

Print This

US generics company Mylan (Nasdaq: MYL) says that its subsidiary in South Africa has launched a comprehensive portfolio of antiretroviral ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in